5-Amino-1MQ 10mg

Description

5-Amino-1MQ (NNMT Inhibitor) Dosage Protocol

5-Amino-1MQ is a small-molecule compound that functions as an inhibitor of NNMT (Nicotinamide N-methyltransferase), an enzyme involved in cellular metabolism and fat storage. By inhibiting NNMT, 5-Amino-1MQ helps increase cellular energy expenditure, reduce fat accumulation, and support metabolic efficiency.

Unlike hormonal peptides, 5-Amino-1MQ works at the cellular metabolic level, making it a unique option for body recomposition, fat loss support, and metabolic optimization without directly altering endocrine pathways such as GH or IGF-1.

This educational protocol outlines a daily subcutaneous approach using a practical dilution for accurate dosing.

---

Reconstitute:
Add 2.0 mL bacteriostatic water → ~5 mg/mL (5000 mcg/mL) concentration (based on a 10 mg vial)

---

Typical Daily Protocol:

• Start: 50 mg per day
• Common range: 50–100 mg daily
• Frequency: Once daily or split into 2 doses (AM/PM)
• Cycle duration: 4–8 weeks commonly used in research settings

---

Easy Measuring:
At 5 mg/mL,

• 1 unit = 0.01 mL ≈ 50 mcg on a U-100 insulin syringe

Example:

• 50 mg dose = 10 mL total (exceeds single vial; typically multiple vials or higher concentration required)

⚠️ Note: Due to higher dosing requirements, users often:

• Use less dilution (e.g., 1 mL instead of 2 mL)
• Or administer via alternative methods (capsules/oral research formats)

---

Administration:

• Subcutaneous injection (if using injectable form)
• Often taken in the morning (fasted) for metabolic support
• Can be split AM/PM for sustained effect

---

Storage:

• Lyophilized: Store at −20 °C (−4 °F)
• After reconstitution: Refrigerate at 2–8 °C (35.6–46.4 °F)
• Protect from light and avoid repeated freeze–thaw cycles

---

Note:
5-Amino-1MQ is commonly researched for fat loss, metabolic enhancement, and body recomposition, particularly due to its role in reducing lipogenesis and increasing cellular energy utilization. It does not significantly impact appetite or hormone levels, making it distinct from GLP-1–based compounds.